First Part IN3,UOC,Seminar Research: Social Media an Rare Disease
http://in3.uoc.edu/opencms_portalin3/opencms/en/activitats/seminaris/agenda/2011/agenda_011
Participatory rural appraisal of livestock diseases amongst a Fulani communit...ILRI
Presented by Bolajoko, M.B., Moses, G.D., Gambari-Bolajoko, K.O., Ifende, V.I., Emenna, P. and Bala, A. at the PENAPH First Technical Workshop, Chiang Mai, Thailand, 11–13 December 2012.
Epidemiology, Triad of epidemiology, Brief epidemiology, Terminology used in Epidemiology, Epidemiology, traid, modes of disease transmission, disease control and prevention, Basic epidemiology, John Snow and Cholera with Epidemiology
Developing Urban Health Indicators for Low Income Countries: A Case Studysteelss
These slides are from a quest lecture given at the Institute for Sustainable Futures at the University of Technology Sydney, Australia (2012).
It gives an overview of my PhD study which was centred on investigating the potential health implications of urbanisation in Vietnam, in addition to exploring NGO engagement with policy makers and government authorities in implementing public health policy.
Fairfax County has seen a rapid growth in the number of Lyme disease cases in recent years. At a recent Lyme disease town hall meeting, the Fairfax County Health Department provided local context, facts and figures about the disease in our community.
Chapter 4Communicable and Noncommunicable Diseases Prevention.docxrobertad6
Chapter 4
Communicable and Noncommunicable Diseases: Prevention and Control of Diseases and Health Conditions
Chapter Objectives (1 of 2)
After studying this chapter, you will be able to:
Explain the differences between communicable (infectious) and noncommunicable (noninfectious) diseases and between acute and chronic diseases and provide examples of each.
Describe and explain communicable and multicausation disease models.
Explain how communicable diseases are transmitted in a community using the “chain of infection” model and use a specific communicable disease to illustrate your explanation.
Explain why noncommunicable diseases are a community and public health concern and provide some examples of important noncommunicable diseases.
Explain the difference between primary, secondary, and tertiary prevention of disease and provide examples of each.
Chapter Objectives (2 of 2)
List and explain the various criteria that communities might use to prioritize their health problems in preparation for the allocation of prevention and control resources.
List and discuss important measures for preventing and controlling the spread of communicable diseases in a community.
List and discuss approaches to noncommunicable disease control in the community.
Define and explain the purpose and importance of health screenings.
Outline a chronic, noncommunicable disease control program that includes primary, secondary, and tertiary disease prevention components.
Introduction
Diseases and other health conditions are classified in several meaningful ways
Classification can lead to prevention and control strategies
Classification of Diseases and Health Problems
In community health, diseases are usually classified as:
Acute or chronic (<3 or >3 months)
Communicable or noncommunicable
Communicable versus Noncommunicable Diseases
Communicable (infectious) diseases – those diseases for which biological agents or their products are the cause and that are transmissible from one individual to another
Noncommunicable (noninfectious) diseases – those illnesses that cannot be transmitted from one person to another
Identifying cause is difficult because many factors can contribute
Acute versus Chronic Diseases and Illnesses
Diseases classified by duration of symptoms
Acute – diseases in which peak severity of symptoms occurs and subsides within 3 months
Can be communicable or noncommunicable
Chronic – diseases or conditions in which symptoms continue longer than 3 months
Can be communicable or noncommunicable
Communicable Diseases
Infectivity: ability of a biological agent to enter and grow in the host
Agent: cause of disease or health problem
Host: susceptible person or organism invaded by an infectious agent
Environment: factors that inhibit or promote disease transmission
Pathogenicity: capability of a communicable agent to cause disease in a susceptible host
Biological Agents of Disease
Communicable Disease Model
Chain of Infectio.
Participatory rural appraisal of livestock diseases amongst a Fulani communit...ILRI
Presented by Bolajoko, M.B., Moses, G.D., Gambari-Bolajoko, K.O., Ifende, V.I., Emenna, P. and Bala, A. at the PENAPH First Technical Workshop, Chiang Mai, Thailand, 11–13 December 2012.
Epidemiology, Triad of epidemiology, Brief epidemiology, Terminology used in Epidemiology, Epidemiology, traid, modes of disease transmission, disease control and prevention, Basic epidemiology, John Snow and Cholera with Epidemiology
Developing Urban Health Indicators for Low Income Countries: A Case Studysteelss
These slides are from a quest lecture given at the Institute for Sustainable Futures at the University of Technology Sydney, Australia (2012).
It gives an overview of my PhD study which was centred on investigating the potential health implications of urbanisation in Vietnam, in addition to exploring NGO engagement with policy makers and government authorities in implementing public health policy.
Fairfax County has seen a rapid growth in the number of Lyme disease cases in recent years. At a recent Lyme disease town hall meeting, the Fairfax County Health Department provided local context, facts and figures about the disease in our community.
Chapter 4Communicable and Noncommunicable Diseases Prevention.docxrobertad6
Chapter 4
Communicable and Noncommunicable Diseases: Prevention and Control of Diseases and Health Conditions
Chapter Objectives (1 of 2)
After studying this chapter, you will be able to:
Explain the differences between communicable (infectious) and noncommunicable (noninfectious) diseases and between acute and chronic diseases and provide examples of each.
Describe and explain communicable and multicausation disease models.
Explain how communicable diseases are transmitted in a community using the “chain of infection” model and use a specific communicable disease to illustrate your explanation.
Explain why noncommunicable diseases are a community and public health concern and provide some examples of important noncommunicable diseases.
Explain the difference between primary, secondary, and tertiary prevention of disease and provide examples of each.
Chapter Objectives (2 of 2)
List and explain the various criteria that communities might use to prioritize their health problems in preparation for the allocation of prevention and control resources.
List and discuss important measures for preventing and controlling the spread of communicable diseases in a community.
List and discuss approaches to noncommunicable disease control in the community.
Define and explain the purpose and importance of health screenings.
Outline a chronic, noncommunicable disease control program that includes primary, secondary, and tertiary disease prevention components.
Introduction
Diseases and other health conditions are classified in several meaningful ways
Classification can lead to prevention and control strategies
Classification of Diseases and Health Problems
In community health, diseases are usually classified as:
Acute or chronic (<3 or >3 months)
Communicable or noncommunicable
Communicable versus Noncommunicable Diseases
Communicable (infectious) diseases – those diseases for which biological agents or their products are the cause and that are transmissible from one individual to another
Noncommunicable (noninfectious) diseases – those illnesses that cannot be transmitted from one person to another
Identifying cause is difficult because many factors can contribute
Acute versus Chronic Diseases and Illnesses
Diseases classified by duration of symptoms
Acute – diseases in which peak severity of symptoms occurs and subsides within 3 months
Can be communicable or noncommunicable
Chronic – diseases or conditions in which symptoms continue longer than 3 months
Can be communicable or noncommunicable
Communicable Diseases
Infectivity: ability of a biological agent to enter and grow in the host
Agent: cause of disease or health problem
Host: susceptible person or organism invaded by an infectious agent
Environment: factors that inhibit or promote disease transmission
Pathogenicity: capability of a communicable agent to cause disease in a susceptible host
Biological Agents of Disease
Communicable Disease Model
Chain of Infectio.
CURRENT PROBLEMS AND ISSUES IN THE DIAGNOSIS OF ORPHAN DISEASES IN CHILDRENindexPub
The review provides current data on the definition and number of orphan diseases in general, around the world, and in individual countries. World data and a small amount of experience from our own research are presented, indicating that rare diseases are complex, chronic diseases that require an interdisciplinary approach, and create many problems for patients, families, clinicians, as well as society and governments.
The benefits of patient involvement in research and development (RE:ACT Congr...jangeissler
Presentation of Jan Geissler, Director EUPATI and Co-Founder CML Advocates Network, about the benefits of involving patients in research and development, and about EUPATI. Held at RE:ACT Conress 2016 on Research of Rare and Orphan Diseases, organized by the Blackswan Foundation on 12 March 2016 in Barcelona, Spain
Epidemiology is the study and analysis of the patterns, causes, and effects of health and disease conditions in defined populations. It is the cornerstone of public health, and shapes policy decisions and evidence-based practice by identifying risk factors for disease and targets for preventive healthcare. Epidemiologists help with study design, collection, and statistical analysis of data, amend interpretation and dissemination of results (including peer review and occasional systematic review). Epidemiology has helped develop methodology used in clinical research, public health studies, and, to a lesser extent, basic research in the biological sciences
Behavior Design Lab-eHealth Center-Open University of CataloniaManuel Armayones
In this presentation, we describe projects and research interests of Behavior Design Lab of the eHealth Center at the Open University of Catalonia (UOC).
We are open to collaborate in consortiums for Horizon Europe RIA projects in the field of eHealth & behavior design & adherence
Please feel free to contact us to further information.
mail: marmayones@uoc.edu Twitter: @armayones
Redes sociales como herramientas de alfabetización digital en salud:algunas b...Manuel Armayones
Presentación realizada en el I Congreso Nacional de la Malformación de Arnold Chiari https://enfermedades-raras.org/index.php/feder-cataluna/9447-inf%C3%B3rmate-sobre-el-i-congreso-nacional-de-malformaci%C3%B3n-de-chiari
Alfabetización Digital en Salud: cuestión de "H-Alma"Manuel Armayones
Tomando la idea de "H-Alma" de los Drs. March y Bimbela de la Escuela Andaluza de Salud Pública reflexionamos en 2017 sobre alfabetización en salud y su vías a través de Internet
¿Cómo pueden combinarse para ayudarnos a cambiar nuestro comportamiento hacia...Manuel Armayones
Presentación en el Cluster for Patient Empowerment. https://www.elsevier.es/corp/conecta/cluster-for-patient-empowerment-futuro-la-psicologia-pasar-la-tecnologia-empoderamiento-del-paciente/
¿Que sabemos sobre la relación entre tecnología y personas?Manuel Armayones
Presentación en mHealth Barcelona https://www.fundacionisys.org/es/mhealth-bcn-conference/conference Hablando sobre Psicología, Salud, Tecnología y Persuasión
Promoción de la Salud y Cambio de Hábitos: Retos permanentes en una sociedad ...Manuel Armayones
Se describen algunas de las dificultades para el cambio de hábitos y se reflexiona sobre la vigencia del abordaje clásico de la promoción de la salud en una sociedad cambiante. Se plantean dudas sobre como nos afectará el uso de asistentes personales (robots) en el ámbito de la promoción de estilos de vida saludables. Se hizo la presentación durante el evento Health4Good de DKV en Noviembre 2016
Psicología 2.0. Retos y Oportunidades. Presentación utilizada en la I Jornada de Psicología 2.0 realizada el 31 de Mayo en el Col.legi Oficial de Psicòlegs de Catalunya.
En esta presentación aparecen algunos de los tópicos del Máster Universitarioen Psicología,Salud y Calidad de Vida. Uso de las TIC en la promoción de la Calidad de Vida de la UOC http://estudios.uoc.edu/es/masters-universitarios/psicologia-salud-calidad-vida-castellano/presentacion
Innovación en investigación en Enfermedades Raras: ePacibard. Inteligencia Co...Manuel Armayones
Presentación en la Mesa 3 de las Jornadas Salud Investiga en la Escuela Andaluza de Salud Pública a cargo de Manuel Armayones (UOC) y Mercedes Serrano (Hospital St.Joan de Déu)
Vídeo en
http://new.livestream.com/easptv/JornadasAndaluzasSaludInvestiga
The APTIC social network has been developed by the PSINET research group at the Universitat Oberta de Catalunya, in collaboration with Hospital de St. Joan de Déu and the Fesalud Foundation. The network aims at enabling the individual members of patients’ associations (mostly parents of children with chronic and rare diseases) to share experiences, information, resources and advice.
In parallel, we created a group on Facebook (APTIC Facebook Group) to publicize the network and analyse differences in the use of the two platforms (APTIC Social Network vs. APTIC Facebook Group)
Looking forward the “classical” e-patient: approach to a typology
Can we combine information from eHealth Literacy Scale with Patient Activation Measure to offer a tailored intervention?
Presentación de Manuel Armayones del Grupo de Investigación Psinet de la Universitat Oberta de Catalunya en el Congreso Medicine 2.0 en la Universidad de Stanford.
Algunas reflexiones sobre el futuro de la eSaludManuel Armayones
Presentación de Manuel Armayones en la II Jornada R+D+I TicSalut organizada en el Parc Científic de la Universitat de Girona per la Fundació TIC-SALUT (Dept.Salut, Generalitat de Catalunya)
Presentación de la sesión sobre Promoción de la Salud y TIC impartida en el marco de unas jornadas organizadas por Proyecto Hombre y el Excmo. Ayuntamiento de Oviedo.
Las Redes Sociales Como Herramientas De IntervencióN Social En SaludManuel Armayones
En el marco del IV Encuentro de Investigación, Innovación e Ingeniería organizado con CINTEL (Centro de Investigación para las Telecomunicaciones) en Bogotá (Colombia) en Agosto 2009 tuvimos la oportunidad de exponer la presentación: Las redes sociales como herramientas de Intervención Social y en Salud.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
1. PsiNET Seminar Research Rare Disease and Social Media: an opportunity for the long tai l Luis Fernandez Luque, PhD Student Norut Tromsø (Norway) Manuel Armayones Ruiz, PhD Grupo de Investigación Psinet- Universitat Oberta de Catalunya (Spain) Co-founder Asociación Española de Síndrome de Lowe [email_address] http://in3.uoc.edu/opencms/opencms/webs/grups_de_recerca/psinet/CA/
2. A disease or disorder is defined as rare in Europe when it affects less than 1 in 2000 citizens (Orphan Drug Regulation 141/2000). Rare diseases may affect 30 million European Union citizens . Rare diseases are characterised by a broad diversity of disorders and symptoms that vary not only from disease to disease but also from patient to patient suffering from the same disease. Relatively common symptoms can hide underlying rare diseases, leading to misdiagnosis .
3. Characteristics of rare diseases Rare diseases are often chronic, progressive, degenerative, and often life-threatening Rare diseases are disabling: the quality of life of patients is often compromised by the lack or loss of autonomy High level of pain and suffering for the patient and his/ her family No existing effective cure There are between 6000 and 8000 rare diseases 50% of rare diseases affect children 80% of rare diseases have identified genetic origins. Other rare diseases are the result of infections (bacterial or viral), allergies and environmental causes, or are degenerative and proliferative.
4. Rare disease patients face common problems: Lack of access to correct diagnosis Delay in diagnosis Lack of quality information on the disease Lack of scientific knowledge of the disease Heavy social consequences for patients Lack of appropriate quality healthcare Inequities and difficulties in access to treatment and care Source: Eurordis
5.
6. Behind the data are real people with real problems http://www.youtube.com/watch?v=M7qirJXWhzc&feature=player_embedded
7.
8. How can things change? By implementing a comprehensive approach to rare diseases By developing appropriate public health policies By increasing international cooperation in scientific research By gaining and sharing scientific knowledge about all rare diseases, not only the most “frequent” ones By developing new diagnostic and therapeutic procedures By raising public awareness By facilitating the network of patient groups to share their experience and best practices By supporting the most isolated patients and their parents to create new patient communities or patient groups By providing comprehensive quality information to the rare disease community Source: Eurordis
Editor's Notes
Brief description: Internet is a common tool in our daily living that offers new possibilities for communicating and delivering health care treatments. One of these possibilities is to use Internet to create a community where professionals (such as psychologists) and caregivers can work together in order to generate processes to improve the quality of life, by providing caregivers with resources to cope with difficult situations. From this perspective, in this session, two projects aimed to improve quality of life of caregivers will be discussed. Psinet is a research group of the Internet Interdisciplinary Institute of the UOC. We work on Psychology, Health and the Net and now we are working on using the internet to improve the quality of life of different groups of people.